Drug Search Results
More Filters [+]

Aprepitant

Alternative Names: aprepitant, emend, mk-869, mk0869, ono-7436, cinvanti, aponvie
Latest Update: 2024-02-14
Latest Update Note: Clinical Trial Update

Product Description

Aprepitant is used with other medications in adults and children 6 months of age and older to prevent nausea and vomiting that may occur after receiving cancer chemotherapy treatment. It is also used with other medications in adults and children 6 months of age and older to prevent delayed nausea and vomiting that may occur several days after receiving certain chemotherapy medications. Aprepitant is not used to treat nausea and vomiting that you already have. Aprepitant is in a class of medications called antiemetics. It works by blocking the action of neurokinin, a natural substance in the brain that causes nausea and vomiting. (Sourced from: https://medlineplus.gov/druginfo/meds/a604003.html)

Mechanisms of Action: NK1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Oncology Unspecified | Oncology Unspecified

Known Adverse Events: Hypotension | Abdominal Pain | Dizziness | Headache | Pain Unspecified | Neutropenia | Dehydration | Asthenia | Constipation | Diarrhea | Dyspepsia | Hiccup | Eructation

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Aprepitant

Countries in Clinic: China, United States, Unknown Location

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Acute Pain|Morphine Dependence|Other|Pain, Postoperative

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

STUDY19030022

P3

Recruiting

Morphine Dependence|Pain, Postoperative|Acute Pain

2024-12-30

DAVINCY

P3

Active, not recruiting

Other

2024-05-18

APHYPAP

P3

Active, not recruiting

Unknown

2020-03-19

CTR20200963

P3

Recruiting

Other

None

Recent News Events